Athyrium Capital Management, L.P. 13F annual report

Athyrium Capital Management, L.P. is an investment fund managing more than $11.3 billion ran by Andrew Hyman. There are currently 2 companies in Mr. Hyman’s portfolio. The largest investments include Biora Therapeutics Inc. and Puma Biotechnology Inc, together worth $11.3 billion.

$11.3 billion Assets Under Management (AUM)

As of 1st August 2024, Athyrium Capital Management, L.P.’s top holding is 10,929,762 shares of Biora Therapeutics Inc. currently worth over $7.21 billion and making up 63.8% of the portfolio value. In addition, the fund holds 1,256,411 shares of Puma Biotechnology Inc worth $4.1 billion, whose value fell 31.0% in the past six months.

Currently, Athyrium Capital Management, L.P.'s portfolio is worth at least $11.3 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Athyrium Capital Management, L.P.

The Athyrium Capital Management, L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Andrew Hyman serves as the Chief Operating Officer and General Counsel at Athyrium Capital Management, L.P..

One of the smallest hedge funds

The two most similar investment funds to Athyrium Capital Management, L.P. are Advent International Corp/ma and Teachers Retirement System Of The State Of Kentucky. They manage $11.2 billion and $11.2 billion respectively.


Andrew Hyman investment strategy

Athyrium Capital Management, L.P.’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 36.2% of the total portfolio value. The fund focuses on investments in the United States as 50.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up approximately 0.1% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $198 million.

The complete list of Athyrium Capital Management, L.P. trades based on 13F SEC filings

These positions were updated on August 8th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security Shares Owned Value Allocation
Biora Therapeutics Inc.
No change
10,929,762
$7,213,643,000 63.78%
Puma Biotechnology Inc
No change
1,256,411
$4,095,900,000 36.22%
No transactions found
Showing first 500 out of 2 holdings